TLX Biopharma · Radiopharma · Cancer imaging · ASX · Thesis updated July 20, 2026

Illuccix funds Telix's bigger radiopharma bet

FY2025 revenue reached US$803.8 million, still led by prostate cancer imaging.
Illuccix remains the cash engine, while Gozellix is meant to protect the franchise after CMS pass-through ended.
Gross margin fell to 53% in 2025 from 65% in 2024 after RLS added lower-margin SPECT products.
Telix lost US$7.1 million after tax in 2025 as R&D and integration costs rose.
The main upside is a wider diagnostic market, especially if BiPASS helps move PSMA PET into first-line prostate cancer diagnosis.
The main overhangs are Zircaix resubmission risk, an SEC subpoena, and a class action lawsuit.

01 Running thesis

A cash engine funding a pipeline

Telix is a radiopharmaceutical company. That means it uses radioactive molecules to find, and in some programs treat, cancer. Today, most of the money comes from diagnostics, not therapies.

The bull case starts with Illuccix. It helped drive FY2025 revenue to US$803.8 million, giving Telix cash to build new imaging agents, a therapy pipeline, and its own supply chain. Gozellix adds a second prostate cancer imaging product and received HCPCS reimbursement effective October 1, 2025, which helps after Illuccix lost CMS pass-through status in July 2025.

The next layer is market expansion. BiPASS could move PSMA PET imaging earlier in prostate cancer diagnosis, where it may replace some invasive biopsies. Management has said that could potentially double the market opportunity for this diagnostic use.

The bear case is that Telix is spending heavily before the pipeline proves itself. The company reported a US$7.1 million loss after tax in FY2025, gross margin fell to 53%, and legal questions now sit beside normal drug approval risk. This is a growth story, but it is not a clean one.

Feb 2026▼FY2025 results added a US$7.1 million loss after tax and a gross margin drop to 53%. The drop was tied to RLS and lower-margin SPECT products, so the growth story now carries more margin risk.

Feb 2026→Q4 commentary kept the main thesis intact. Revenue reached US$803.8 million and Zircaix is being prepared for resubmission, but legal risk rose after the November 2025 class action.

Aug 2025▲Telix launched Gozellix and said its HCPCS code would be effective October 1, 2025. That helped offset concern after Illuccix pass-through ended.

Aug 2025▼The SEC subpoena became a clearer overhang. It requests documents mainly related to disclosure activity for prostate cancer therapeutic candidates.

Feb 2025→Telix shifted reporting into Therapeutics, Precision Medicine, and Telix Manufacturing Solutions. The structure better fits the vertical model, but the business was still highly concentrated in U.S. Illuccix sales.

Feb 2025▲The RLS acquisition added 31 U.S. pharmacies and strengthened Telix's distribution footprint. Management also set out a two-product strategy around Illuccix and Gozellix.

Aug 2024▲The starting thesis was built around strong Illuccix sales, new imaging agents, and vertical integration. Management pointed to a larger addressable market across renal, brain, and prostate cancer imaging.

02 Business model

Diagnostics pay for the buildout

Telix makes money by selling imaging agents used by hospitals and imaging centers. A patient receives the agent, then a scan helps doctors see where cancer may be. Illuccix and Gozellix are the commercial center of this model today.

The company is trying to own more of the system around those products. It bought ARTMS, ITG, and RLS, including 31 U.S. radiopharmacies from RLS. That gives Telix more control over manufacturing, local distribution, and future therapy delivery.

This vertical model can help if volume keeps rising. It can also hurt margins while the network is being integrated. In 2025, gross margin dropped to 53% from 65% because RLS added lower-margin SPECT imaging products to the sales mix.

The harder model shift is from diagnostics to therapies. Diagnostics can create revenue now. Therapies like TLX591 still need clinical success, regulatory approval, manufacturing reliability, and payment support before they can become large commercial products.

03 Product portfolio

From scans to treatment

Cash cow

Illuccix

Illuccix is Telix's main commercial prostate cancer imaging product. It has funded the wider company buildout, but the July 2025 end of CMS pass-through status makes pricing and reimbursement a key watch item.

Growth engine

Gozellix

Gozellix is the new prostate cancer imaging product in Telix's two-product strategy. Its HCPCS code became effective on October 1, 2025, giving Telix a reimbursement tool as Illuccix faces more pressure.

Option

Zircaix

Zircaix is a renal cancer imaging candidate. It received a CRL, which is an FDA rejection letter asking for fixes, but management says it is preparing to resubmit the BLA shortly after a Type A meeting.

Option

Pixclara

Pixclara is Telix's brain cancer imaging program. It is part of the plan to move beyond prostate cancer and build a broader precision medicine franchise.

Option

BiPASS

BiPASS tests whether MRI plus PSMA PET can be used in front-line prostate cancer diagnosis. If it works, Telix believes it could significantly broaden the market and potentially double the opportunity.

Option

TLX591

TLX591 is Telix's lead prostate cancer therapy candidate. It is in the Phase III ProstACT GLOBAL study, with Part 2 open for enrollment.

Option

TLX250 and TLX101

TLX250 targets renal cancer and TLX101 targets glioblastoma. These programs show the wider therapy ambition, but they still carry clinical and approval risk.

04 Business segments

One segment still pays most bills

Precision Medicine78%growing fast

Telix Manufacturing Solutions21%growing fast

Therapeutics1%modest

The mix below uses FY2025 reportable segment revenue. Precision Medicine still dominates, while Telix Manufacturing Solutions became meaningful after RLS and Therapeutics remains early.

05 Risk factors

What could break the thesis

Illuccix reimbursement pressure

High impact · Medium odds

Illuccix lost CMS pass-through status in July 2025. Telix says commercial actions and Gozellix reimbursement should soften the hit, but the market still needs to prove that demand and pricing can hold. If customers switch, delay scans, or push back on price, the cash engine weakens.

We watchQuarterly Illuccix and Gozellix volume, average selling price, and management comments on CMS payment pressure.

RLS margin drag

Medium impact · High odds

RLS gives Telix 31 U.S. pharmacies and more control over distribution. It also brought lower-margin SPECT products into the mix. Gross margin fell to 53% in 2025 from 65% in 2024, so investors need to see whether scale improves the economics.

We watchGross margin, TMS revenue mix, and any disclosure on RLS integration costs.

Zircaix resubmission slips

Medium impact · Medium odds

Zircaix already received a CRL from the FDA. Management says it is preparing to resubmit the BLA shortly, but the agency still has to accept the fixes and review the product again. Another delay would slow Telix's move beyond prostate cancer imaging.

We watchFormal Zircaix BLA resubmission, FDA acceptance, and any new FDA questions on manufacturing.

Therapy pipeline disappointment

High impact · Medium odds

The long-term upside depends on radioligand therapies such as TLX591, TLX250, and TLX101. These are harder than diagnostics because they must show patient benefit, safe dosing, reliable supply, and payer support. Failure in ProstACT GLOBAL would cut into the biggest therapy part of the story.

We watchProstACT GLOBAL enrollment, interim updates if disclosed, safety signals, and trial completion timing.

SEC and class action overhang

Medium impact · Medium odds

Telix has an SEC subpoena requesting documents mainly tied to disclosure activity for prostate cancer therapeutic candidates. A securities class action, Thomas v. Telix Pharmaceuticals, was filed in November 2025 and alleges the company overstated pipeline progress before the subpoena and Zircaix CRL. Management says it is fully cooperating, but legal matters can distract the company and affect investor trust.

We watchSEC updates, court filings in Thomas v. Telix Pharmaceuticals, and any change in management's disclosure language.

06 Quick answers

In one breath

What does Telix Pharmaceuticals actually sell?

Telix sells radioactive imaging agents used to help doctors see cancer on scans. Its key commercial products today are Illuccix and Gozellix for prostate cancer imaging.

Why does Illuccix reimbursement matter so much?

Illuccix has been Telix's main cash engine. Its CMS pass-through status ended in July 2025, so investors are watching whether Gozellix reimbursement and sales actions can protect revenue and margins.

Is Telix profitable?

Telix reported a US$7.1 million loss after tax for FY2025. Revenue grew strongly, but R&D spending, RLS integration, and a lower-margin product mix weighed on profit.

What is the biggest upside case for Telix?

The biggest upside is that Telix turns a strong diagnostic franchise into a broader cancer platform. BiPASS could expand prostate cancer imaging, and therapy programs like TLX591 could open a larger treatment market if trials succeed.